Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.04 USD | -3.32% |
|
-5.56% | -70.52% |
07-08 | Immix Biopharma Doses First Patient in US AL Amyloidosis Trial With NXC-201 | MT |
07-08 | Immix Biopharma, Inc. Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-70.52% | 53.89M | |
+7.40% | 101B | |
+7.76% | 42.18B | |
-14.37% | 32.26B | |
+80.23% | 29.79B | |
-12.27% | 16.06B | |
+2.33% | 14.45B | |
-8.56% | 12.01B | |
+182.74% | 10.71B | |
+3.82% | 8.89B |
- Stock Market
- Equities
- IMMX Stock
- News Immix Biopharma, Inc.
- Immix Biopharma Doses First Patient in US AL Amyloidosis Trial With NXC-201